Cefovecin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Cefovecin
Cefovecin.svg
Systematic (IUPAC) name
(7R)-7-([(2Z)- 2-(2-amino- 1,3-thiazol- 4-yl)- 2-methoxyiminoacetyl]amino)- 8-oxo- 3-[(2S)-oxolan- 2-yl]- 5-thia- 1-azabicyclo[4.2.0]oct- 2-ene- 2-carboxylic acid
Clinical data
AHFS/Drugs.com International Drug Names
Pregnancy cat. do not administer to pregnant cat or during breeding or lactation period.
Legal status veterinary prescription only
Routes dorsoscapular subcutaneous injection
Pharmacokinetic data
Protein binding Dogs: 98.5%, Cats: 99.8%
Metabolism none
Half-life Dogs: 133 hours, Cats: 166 hours
Excretion unchanged in urine/bile
Identifiers
CAS number 234096-34-5 YesY
ATCvet code QJ01DD91
PubChem CID 9577223
ChemSpider 7851662 N
UNII 0D1OL46ZIE YesY
ChEMBL CHEMBL2104475 N
Chemical data
Formula C17H19N5O6S2 
Mol. mass 453.49 g/mol
 N (what is this?)  (verify)

Cefovecin (INN) is an antibiotic of the cephalosporin class, licensed for the treatment of skin infections in cats and dogs. It is marketed by Zoetis under the trade name Convenia. It is the first single-dose injectable antibiotic for dogs and cats that assures owner compliance with dosing for the animal. It is used for the treatment of skin infections caused by Pasturella multocida in cats, and Streptococcus intermedius/S. canis in dogs. The advantage of using injectable antibiotics is not missing a dose that can allow partially resistant microbes to recover during missed doses. It is highly effective, but should not be used in pregnant or lactating animals or in animals with a history of allergies to penicillin or cephalosporin drugs.[1]

Approval and usage[edit]

Cefovecin was first authorized for use in the European Union in June 2006,[2] and was approved for use in the United States in June 2008.[3]

It is approved as a broad-spectrum, fourth-generation cephalosporin for subcutaneous injection lasting 14 days for treating skin and soft tissue infections.[4]

Precautions[edit]

Contraindications include known allergies to cefovecin or antibiotics containing β-lactam rings such as penicillin or cephalosporins. Adverse reactions can include anaphylaxis that requires long-term treatment due to the long clearance time of 65 days. It is not for use in humans and should be kept out of reach of children. Individuals with similar known allergies should avoid dermal contact when handling the drugs.

Adverse reactions in dogs can include lethargy, decreased appetite, vomiting, diarrhea, blood in feces, and flatulence. Adverse reactions in cats can include vomiting, diarrhea, decreased appetite, lethargy, odd hyperactive behavior, and inappropriate urination. Mildly increased serum ALT and gamma glutamyl transferase have been noted.[5]

Effectiveness[edit]

Cefovecin functions by interfering with cell wall synthesis. The chemical covalently binds to the so-called penicillin-binding proteins. Due to the high protein-binding of the chemical, it is not effective against E. coli, Pseudomonas spp., or enterococci.

In drug studies, cefovecin administered to dogs was 92.4% effective against skin infections (secondary superficial pyoderma, abscesses, and infected wounds). In cats, it was 96.8% effective against skin infections.[6]

References[edit]

  1. ^ Pfizer Animal Health. "Pfizer Convenia". Pfizer. Retrieved 29 January 2013. 
  2. ^ "European Public Assessment Report for Convenia (from the EMEA website)". Retrieved 2008-07-11. 
  3. ^ "FDA Approves First and Only Single-dose Antibiotic for Dogs and Cats" (Press release). Pfizer Inc. 2008-06-30. Retrieved 2008-07-11. 
  4. ^ Pfizer Animal Health. "Convenia". Pfizer. Retrieved 29 January 2013. 
  5. ^ Pfizer Animal Health. "Pfizer Convenia". Pfizer. Retrieved 29 January 2013. 
  6. ^ Pfizer Animal Health. "Pfizer Convenia". Pfizer. Retrieved 29 January 2013. 

External links[edit]